Innate Pharma IPHA Income Statement (2017-2026)

NASDAQ IPHA
$1.60 -0.10 (-5.88%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Innate Pharma Quarterly Income Statement

Periods 17 quarters
Latest Jun 2026

Innate Pharma reported net income of -$22.81M for the quarter ended Jun 2026. This income statement covers 17 quarters of results from Dec 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2017 Dec2018 Jun2019 Dec2019 Jun2020 Dec2020 Jun2021 Dec2021 Jun2022 Dec2022 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025 Dec2025 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 57.61M63.94M78.58M78.99M79.54M79.54M80.45M83.83M93.72M
Revenue & cost
Revenue 0.81M60.19M0.01M0.01M0.02M
Operating items
Research & DevelopmentR&D -41.11M-87.27M-34.69M-59.27M-26.25M-53.77M-26.63M-52.71M-34.25M-60.28M-31.31M-55.55M-23.23M-50.78M-19.62M
Wages, Salaries and OtherWages -0.94M
Selling, General & AdministrativeSG&A -10.44M-28.56M-15.96M-22.64M-23.27M-29.20M-12.95M-22.89M-9.96M-19.68M-10.32M-21.07M-11.06M-22.58M-9.06M
Other Operating ExpensesOther Opex 0.000.000.00M0.000.00M
Operating ExpensesOpex -51.55M-115.83M-50.66M-81.90M-49.51M-82.97M-39.58M-75.60M-44.21M-79.95M-41.63M-76.61M-34.28M-73.35M-28.68M
Operating IncomeOp. Inc -9.19M-30.62M-54.71M-0.43M-28.34M-28.78M-22.10M
EBIT -28.49M-9.19M-9.05M-30.62M-54.71M-64.57M-0.43M-10.12M-28.34M-57.11M-28.78M-60.88M-22.10M
Non-operating items
Non Operating Interest Expenses -2.17M-5.51M-4.88M-8.06M-2.14M-4.57M-6.58M-5.43M-1.05M-1.97M-2.22M-4.25M-3.17M-3.63M-1.62M
Goodwill impairment chargesGoodwill Impair. -29.94M-74.01M-54.71M-58.59M-13.63M-55.11M-62.87M
Net income details
EBT -22.98M-11.38M-0.99M-28.56M-52.03M-59.15M0.62M-8.14M-26.67M-52.86M-24.16M-57.24M-22.81M
Profit After TaxPAT -22.98M-11.38M-0.99M-28.56M-52.03M-59.15M0.62M-8.14M-26.67M-52.86M-24.16M-57.24M-22.81M
Income from Continuing OperationsIncome (Continuing) -22.98M-11.38M-0.99M-28.56M-52.03M-59.15M0.62M-8.14M-26.67M-52.86M-24.16M-57.24M-22.81M
Income from Discontinued OperationsIncome (Discontinued) -75.30M-8.39M-0.08M-0.13M
Consolidated Net IncomeConsol Net Inc. -22.98M-11.38M-76.29M-28.56M-60.41M-0.08M-59.28M0.62M-8.14M-26.67M-52.86M-24.16M-57.24M-22.81M
Income towards Parent CompanyParent Net Inc 3.48M-22.98M-11.38M-76.29M-28.56M-60.41M-0.08M-59.28M0.62M-8.14M-26.67M-52.86M-24.16M-57.24M-22.81M
Net Income towards Common StockholdersNet Income 3.48M-22.98M-11.38M-76.29M-28.56M-60.41M-0.08M-59.28M0.62M-8.14M-26.67M-52.86M-24.16M-57.24M-22.81M
Additional items
EPS (Basic) 0.06-0.34-0.17-0.97-0.36-0.760.00-0.740.01-0.10-0.33-0.65-0.30-0.64-0.25
Shares Outstanding 54.35M58.78M58.78M66.91M66.91M78.93M78.93M79.54M79.54M79.64M79.64M80.45M80.45M81.05M81.05M89.59M89.59M
Interest ExpensesInt Expense -2.17M-5.51M-4.88M-8.06M-2.14M-4.57M-6.58M-5.43M-1.05M-1.97M-2.22M-4.25M-3.17M-3.63M-1.62M

Innate Pharma Income Statement API

Pull Innate Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=IPHA&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY